Labcorp Holdings Inc. (LH) Net Profit Margin: 6.66%
Is Labcorp Holdings Inc.’s net profit margin high or low?
Labcorp Holdings Inc.'s net profit margin of 6.66% is 28% below its 5-year average of 9.24%, near the low end of its 5-year range (3.44%–18.10%).
As of Sunday, June 14, 2026. 10.91% above its 12-month average of 6.01%.
LH Net Profit Margin Chart
LH Average Net Profit Margin Chart
LH Current vs Average Net Profit Margin Chart
LH Net Profit Margin Metrics
NET PROFIT MARGIN
6.66%
NET PROFIT MARGIN AVG TTM
6.01%
NET PROFIT MARGIN AVG 3Y
6.56%
NET PROFIT MARGIN AVG 5Y
9.24%
NET PROFIT MARGIN AVG 10Y
8.65%
NET PROFIT MARGIN AVG 15Y
9.02%
NET PROFIT MARGIN AVG 20Y
9.60%
CURRENT VS TTM AVG
+10.91%
CURRENT VS 3Y AVG
+1.56%
CURRENT VS 5Y AVG
-27.95%
CURRENT VS 10Y AVG
-23.01%
CURRENT VS 15Y AVG
-26.18%
CURRENT VS 20Y AVG
-30.62%
LH Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Labcorp Holdings Inc. (LH) | $21.83B | 6.66% | 6.01% | 6.56% | 9.24% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 21.40% | 21.94% | 21.74% | 21.20% |
| BioNTech SE (BNTX) | $22.90B | -44.73% | -31.89% | 3.77% | 12.08% |
| United Therapeutics Corporation (UTHR) | $23.17B | 40.61% | 41.73% | 40.84% | 37.71% |
| Waters Corporation (WAT) | $23.17B | 11.91% | 20.93% | 21.85% | 22.39% |
| Moderna, Inc. (MRNA) | $19.80B | -143.55% | -128.24% | -70.25% | -50.87% |
| Veeva Systems Inc. (VEEV) | $25.92B | 28.37% | 27.22% | 24.83% | 24.72% |
| Hologic, Inc. (HOLX) | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| DexCom, Inc. (DXCM) | $29.08B | 19.31% | 16.12% | 14.73% | 15.57% |
| Biogen Inc. (BIIB) | $29.53B | 13.92% | 15.03% | 17.95% | 19.29% |
Margin Comparison
Operating Margin
11.0%
Net Profit Margin
6.7%
Labcorp Holdings Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Labcorp Holdings Inc. Net Profit Margin FAQ
- What is the net profit margin for Labcorp Holdings Inc. (LH)?
- The net profit margin for LH stock is 6.66%.
- Is Labcorp Holdings Inc.'s net profit margin high or low?
- Labcorp Holdings Inc.'s net profit margin of 6.66% is 28% below its 5-year average of 9.24%, near the low end of its 5-year range (3.44%–18.10%).
- What is the TTM average net profit margin for Labcorp Holdings Inc. (LH)?
- The TTM average net profit margin for LH stock is 6.01%.
- What is the 3Y average net profit margin for Labcorp Holdings Inc. (LH)?
- The 3Y average net profit margin for LH stock is 6.56%.
- What is the 5Y average net profit margin for Labcorp Holdings Inc. (LH)?
- The 5Y average net profit margin for LH stock is 9.24%.
- What is the 10Y average net profit margin for Labcorp Holdings Inc. (LH)?
- The 10Y average net profit margin for LH stock is 8.65%.
- What is the 15Y average net profit margin for Labcorp Holdings Inc. (LH)?
- The 15Y average net profit margin for LH stock is 9.02%.
- What is the 20Y average net profit margin for Labcorp Holdings Inc. (LH)?
- The 20Y average net profit margin for LH stock is 9.60%.
Labcorp Holdings Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 6.28% |
| 2024-12-31 | 5.73% |
| 2023-12-31 | 3.44% |
| 2022-12-31 | 10.78% |
| 2021-12-31 | 18.10% |
| 2020-12-31 | 11.13% |
| 2019-12-31 | 7.13% |
| 2018-12-31 | 7.80% |
| 2017-12-31 | 12.15% |
| 2016-12-31 | 7.59% |
| 2015-12-31 | 5.03% |
| 2014-12-31 | 8.50% |
| 2013-12-31 | 9.88% |
| 2012-12-31 | 10.28% |
| 2011-12-31 | 9.38% |
| 2010-12-31 | 11.16% |
| 2009-12-31 | 11.57% |
| 2008-12-31 | 10.31% |
| 2007-12-31 | 11.72% |
| 2006-12-31 | 12.02% |
| 2005-12-31 | 11.61% |
| 2004-12-31 | 11.77% |
| 2003-12-31 | 10.92% |
| 2002-12-31 | 10.15% |
| 2001-12-31 | 8.16% |
| 2000-12-31 | 5.84% |
| 1999-12-31 | 3.85% |
| 1998-12-31 | 4.27% |
| 1997-12-31 | -7.04% |
| 1996-12-31 | -9.55% |
Related Metrics
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter